Regulation of EGFR protein stability by the HECT-type ubiquitin ligase smurf21,2

Neoplasia

Volumn 13, Issue 7, 2011, Pages 570-578

  Ray, Dipankar ^a   Ahsan, Aarif ^a   Helman, Abigail ^a   Chen, Guoan ^a   Hegde, Ashok ^a   Gurjar, Susmita Ramanand ^a   Zhao, Lili ^a   Kiyokawa, Hiroaki ^b   Beer, David G ^a   Lawrence, Theodore S ^a   Nyati, Mukesh K ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; SMALL INTERFERING RNA; SMURF2 PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; CANCER CELL; CELL SURVIVAL; CHO CELL; CONTROLLED STUDY; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TISSUE MICROARRAY; TUMOR GROWTH; UBIQUITINATION;

EID: 79960060557     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11632     Document Type: Article

References (47)

1. Zwick E, Bange J, and Ullrich A (2001). Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8, 161-173.
2. Grandis JR and Tweardy DJ (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53, 3579-3584.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, and Franklin WA (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21, 3798-3807.
4. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, and Siu LL (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22, 77-85.
5. Ciardiello F and Tortora G (2008). EGFR antagonists in cancer treatment.N Engl J Med 358, 1160-1174.
6. Harari PM (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11, 689-708.
7. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, and Nyati MK (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869.
8. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, and Nyati MK (2009). Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res 69, 5108-5114.
9. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, and Nyati MK (2006). Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66, 981-988.
10. Busino L, Chiesa M, Draetta GF, and Donzelli M (2004). Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23, 2050-2056.
11. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, and Draetta GF (2003). Degradation of Cdc25A by ß-TrCP during S phase and in response to DNA damage. Nature 426, 87-91.
12. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, and Draetta GF (2002). Dual mode of degradation of Cdc25 A phosphatase. EMBO J 21, 4875-4884.
13. Sehat B, Andersson S, Girnita L, and Larsson O (2008). Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68, 5669-5677.
14. Monami G, Emiliozzi V, and Morrione A (2008). Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 216, 426-437.
15. [Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, and Yarden Y (1998). c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12, 3663-3674.
16. Inoue Y and Imamura T (2008). Regulation of TGF-ß family signaling by E3 ubiquitin ligases. Cancer Sci 99, 2107-2112.
17. Rotin D and Kumar S (2009). Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 10, 398-409.
18. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, and Wrana JL (2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6, 1365-1375.
19. Izzi L and Attisano L (2004). Regulation of the TGFß signalling pathway by ubiquitin-mediated degradation. Oncogene 23, 2071-2078.
20. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, and Derynck R (2001). Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 98, 974-979.
21. Osmundson EC, Ray D, Moore FE, Gao Q, Thomsen GH, and Kiyokawa H (2008). The HECT E3 ligase Smurf2 is required for Mad2-dependent spindle assembly checkpoint. J Cell Biol 183, 267-277.
22. Moore FE, Osmundson EC, Koblinski J, Pugacheva E, Golemis EA, Ray D, and Kiyokawa H (2010). The WW-HECT protein Smurf2 interacts with the docking protein NEDD9/HEF1 for Aurora A activation. Cell Div 5, 22.
23. Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavsak P, Rasmussen RK, Seet BT, Sicheri F, and Wrana JL (2005). Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell 19, 297-308.
24. Liu X, Lee J, Cooley M, Bhogte E, Hartley S, and Glick A (2003). Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 63, 7760-7768.
25. Cassell A and Grandis JR (2010). Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 19, 709-722.
26. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, and Ooi A (2006). EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118, 1173-1180.
27. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, and Kuwano H (2002). High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 62, 7162-7165.
28. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, and Kiyokawa H (1999). Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 19, 7011-7019.
29. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, and Nyati MK (2007). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26, 3431-3439.
30. Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS, and Kiyokawa H (2001). The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signalregulating kinase 1. Mol Cell Biol 21, 4818-4828.
31. Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, Zou X, Ghosh AK, Varga J, Draetta GF, et al. (2005). Transforming growth factor beta facilitates ß-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 25, 3338-3347.
32. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, and Lawrence TS (2004). Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10, 691-700.
33. Hahnfeldt P, Panigrahy D, Folkman J, and Hlatky L (1999). Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59, 4770-4775.
34. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al. (2008). Gene expression- based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14, 822-827.
35. Camp RL, Chung GG, and Rimm DL (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8, 1323-1327.
36. Wiesner S, Ogunjimi AA, Wang HR, Rotin D, Sicheri F, Wrana JL, and Forman- Kay JD (2007). Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. Cell 130, 651-662.
37. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, and Hung MC (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393.
38. Tanida I, Ueno T, and Kominami E (2008). LC3 and autophagy. Methods Mol Biol 445, 77-88.
39. Kimura S, Fujita N, Noda T, and Yoshimori T (2009). Monitoring autophagy in mammalian cultured cells through the dynamics of LC3. Methods Enzymol 452, 1-12.
40. Di Guglielmo GM, Le Roy C, Goodfellow AF, and Wrana JL (2003). Distinct endocytic pathways regulate TGF-ß receptor signalling and turnover. Nat Cell Biol 5, 410-421.
41. Sorkin A and Goh LK (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315, 683-696.
42. Lauwers E, Jacob C, and Andre B (2009). K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J Cell Biol 185, 493-502.
43. Barriere H, Nemes C, Du K, and Lukacs GL (2007). Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery. Mol Biol Cell 18, 3952-3965.
44. Huang F, Kirkpatrick D, Jiang X, Gygi S, and Sorkin A (2006). Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 21, 737-748.
45. Argenzio E, Bange T, Oldrini B, Bianchi F, Peesari R, Mari S, Di Fiore PP, Mann M, and Polo S (2011). Proteomic snapshot of the EGF-induced ubiquitin network. Mol Syst Biol 7, 462.
46. Alwan HA and van Leeuwen JE (2007). UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. J Biol Chem 282, 1658-1669.
47. McCullough J, Clague MJ, and Urbe S (2004). AMSH is an endosome-associated ubiquitin isopeptidase. J Cell Biol 166, 487-492.